Arginine
| Evidence Level: L4 | Predicted Indications: 1 |
Table of Contents
Arginine: From Parenteral Nutrition Amino Acid Supply to Gastroparesis
One-Sentence Summary
Arginine is an amino acid that is marketed in Canada, mainly as a component of parenteral nutrition solutions and as an injectable product. The TxGNN model predicts it may be effective for gastroparesis, but there are currently 0 registered clinical trials and only 8 publications, all preclinical or case-level, supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Canadian licence data compiled for this report |
| Predicted New Indication | Gastroparesis |
| TxGNN Prediction Score | 0.9942 |
| Evidence Level | L4 |
| Canada Market Status | Marketed (marketed DINs on record: at least 20) |
| Number of DINs | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known biology, arginine is the substrate of nitric oxide synthase (NOS). Neuronal NOS (nNOS) in nitrergic inhibitory neurons helps drive gastric relaxation, pyloric sphincter relaxation and gastric accommodation.
Preclinical studies link gastroparesis to impaired nitrergic signalling:
- Glucocorticoid-induced gastroparesis in mice was associated with depletion of L-arginine (PMID 25057793).
- Impaired nitrergic relaxation of the pyloric sphincter was reported in a Parkinson’s disease rat model (PMID 35380456).
- Reduced nNOS function and myenteric neuropathy have been discussed as mechanisms in diabetic gastroparesis (PMID 18312542, PMID 21193530).
This supports biological plausibility for supplementing the arginine/nitric oxide pathway. However, no human interventional data show that arginine improves gastric emptying or symptoms. The high TxGNN score is a computational prediction and does not replace clinical evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
All publications below are preclinical or case reports. No RCTs or human interventional studies were identified.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 25057793 | 2014 | Animal study (mouse) | Endocrinology | Glucocorticoids induced gastroparesis in mice through depletion of L-arginine |
| 35380456 | 2022 | Animal study (rat) | Am J Physiol Gastrointest Liver Physiol | Impaired nitrergic relaxation of the pyloric sphincter in a Parkinson’s disease rat model with gastroparesis |
| 18312542 | 2008 | Animal study (rat) | Neurogastroenterol Motil | Myenteric neuropathy and nNOS changes in the jejunum of spontaneously diabetic BB-rats |
| 21193530 | 2011 | Animal study | Am J Physiol Gastrointest Liver Physiol | Hyperglycaemia inhibits gastric motility via nodose ganglia KATP channels |
| 18322959 | 2008 | Animal study (mouse) | World J Gastroenterol | Gastric motor effects of ghrelin and GHRP-6 in diabetic mice with gastroparesis |
| 19023028 | 2009 | Animal study (dog) | Am J Physiol Gastrointest Liver Physiol | Synchronized gastric electrical stimulation improved vagotomy-induced impaired accommodation via the nitrergic pathway |
| 31984783 | 2020 | Animal study (rat) | Am J Physiol Gastrointest Liver Physiol | Sacral nerve stimulation increased gastric accommodation via spinal afferent and vagal efferent pathways |
| 8194696 | 1994 | Animal study (rat) | Gastroenterology | Gastric motor response to food protein-induced anaphylaxis |
| 33867519 | 2021 | Case report | Am J Case Rep | Lifestyle changes normalised serum lactate in an m.3243A>G carrier (indirect relevance) |
Canada Market Information
Arginine is authorised in Canada under 20 single-ingredient licences, all valid. The licence data compiled for this report do not include dosage form or approved indication text. Main authorisations:
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 00399736 | L-Arginine Hydrochloride Injection | Not listed | Not listed |
| 02046709 | Clinimix | Not listed | Not listed |
| 00872296 | Travasol | Not listed | Not listed |
| 02236875 | Primene 10% | Not listed | Not listed |
| 02477947 | Olimel 7.6% | Not listed | Not listed |
Other authorised products include further Clinimix and Clinimix E strengths, 20% Prosol, Essepna, Olimel 5.7% and SmofKabiven Extra Nitrogen Electrolyte Free.
Safety Considerations
Package insert warnings, contraindications and drug interaction data were not available for this report. Please refer to the package insert for safety information.
The TxGNN knowledge graph also flags the following conditions as potential contraindications (graph-based associations, not label text). They should be verified against the product labelling:
- Renal: kidney disease, chronic kidney disease, chronic renal failure, end-stage renal failure, nephrolithiasis, nephrocalcinosis, acute urate nephropathy
- Calcium and bone: hypercalcaemia, humoral hypercalcaemia of malignancy, hyperparathyroidism, osteitis fibrosa, sarcoidosis, lytic metastatic bone lesion
- Acid-base and metabolic: metabolic acidosis, renal tubular acidosis, acidosis disorder, phosphorus metabolism disease, phenylketonuria and other disorders of phenylalanine metabolism
- Cardiovascular: heart disease, cardiovascular disease, ventricular fibrillation, digitalis poisoning
- Haematological: sickle cell anaemia, hereditary persistence of fetal haemoglobin
- Other: constipation disorder
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is biologically plausible through the nitric oxide pathway, but the evidence is limited to animal and mechanistic studies. There are no clinical trials and no human data showing benefit. Package insert safety data are also missing, and the knowledge graph flags many potential contraindications, notably renal and cardiovascular conditions.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications, which is currently a blocking gap
- Mechanism of action data from DrugBank
- Human evidence, such as a pilot or Phase 2 study of arginine or NO-pathway supplementation in gastroparesis, and a search of international trial registries
- Confirmation of available routes (the current Canadian products are largely parenteral) against the route a gastroparesis therapy would require
- A safety plan for patients with renal, cardiovascular or metabolic comorbidities, including diabetic patients, who are the main gastroparesis population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.